This report suggests that advanced prostate cancer may be newly diagnosed after holmium laser enucleation of the prostate. Even if prostate cancer had not been demonstrated in the enucleated specimen, and postoperative PSA levels were below the standard values, physicians should regularly monitor ...
Immunohistochemical examination of the initial biopsy specimens revealed that 4 and 3 cases were positive for CEA and chromogranin A, respectively. In advanced prostate cancer patients with low PSA level, those markers may aid in the follow up of disease. 展开 ...
PSA 90 ng/mL; Hb 9.4 g/dL; ANC 1.5 Liver function tests continue to be abnormal Diagnosis of Recurrence Patient is diagnosed with biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease Germline genetic testing is negative Treatment for Recurrence ...
Prostate-specific antigen (PSA) is well known as a specific tumor marker for prostate cancer, but carcinoembryonic antigen (CEA)- and carbohydrate antigen 19-9 (CA19-9)-elevating adenocarcinomas originating in the prostate gland are rare. We report a case of metastatic adenocarcinoma of the prost...
news Olaparib Combo Improves PFS in Metastatic Prostate Cancer news Small PFS Gain in Metastatic Prostate Cancer With TKI, ICI news Radium-223 Plus EnzalutamideUps Survival in Metastatic Prostate Cancer news Genetic Testing Rates Low in Metastatic Castration-Resistant Prostate Cancer Related Conditio...
Overall, 20% of the patients treated reached the primary endpoint — undetectable prostate-specific antigen (PSA) and noncastrate levels of testosterone at 20 months, which the authors described as "no evidence of disease" (NED). This endpoint "could not have been achieved with any single thera...
Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer It is currently unclear if early prostate-specific antigen (PSA) or pain improvements are adequate surrogates for overall survival in men with metastatic h......
Abiraterone (AA) is indicated in mRCPC (metastatic castration-resistant prostate cancer) before or after chemotherapy, and in mHSPC (metastatic hormone-sensitive prostate cancer) as first line. A decrease in PSA is associated with improved clinical response and increased survival. Recent studies have...
PSA responses have been associated with a survival benefit in patients treated with enzalutamide in retrospective analyses.However the prognostic value of PSA declines in highly pretreated patients receiving enzalutamide remains to be defined.Medical records of patients with documented mCRPC treated with enz...
Prostate Cancer | Case Based Peer Perspectives | A 75-year-old Man with Prostate Cancer Estradiol and Hormone Therapy Show Similar PSA Response in Prostate Cancer Spencer Feldman February 15th 2025 Article Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy ...